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Abstract
Background
Authors of clinical practice guidelines (CPGs) disclose financial conflicts of interest (FCOIs)
to promote transparency ethics. Typically, they do so on standard declaration forms contain-
ing generic open-ended questions on FCOIs. Yet, the literature is scant on the format and
effect of alternative disclosure forms. Does supplementing a standard form with subsequent
detailed disclosure forms tailored to the context of the CPG improve the yield or accuracy of
FCOIs declarations?
Methods
For an international CPG in gastroenterology on the endoscopic surveillance for colorectal
neoplasia in inflammatory bowel disease, we compared the use of a standard FCOIs disclo-
sure form with a contextual FCOIs disclosure form that detailed commercial relations related
to the CPG topic. This included manufacturers of endoscopes, endoscopy equipment and
accessories. Participants completed the generic form early, and the supplementary contex-
tual form six months later. We then compared the FCOI disclosures obtained.
Findings
26 participants provided FCOIs disclosures using both disclosure forms. We found discrep-
ancies regarding (1) the disclosure of FCOIs (presence/absence), and (2) the listing of
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financial entities. While the number of participants who disclosed a FCOI remained the
same (30.8%) using the two forms, disclosures were not from the same individuals: two
additional participants disclosed a FCOI, whereas two participants withdrew previous disclo-
sures. Among those who reported a FCOI in either form, we noted inconsistencies in disclo-
sures for 70% of the participants. This included changes in FCOIs disclosure status or
modifications of "their commercial relations".
Discussion
Accurate reporting of FCOIs advances the transparency and ethical integrity of CPGs. Our
experience suggests that a contextual FCOIs disclosure form tailored to content of the CPG
with narrow, detailed questions provides supplementary, more complete FCOIs declara-
tions than generic forms alone. The finding raises challenges on how forms are best written
and formatted, optimally timed, and more effectively processed with sensitivity to profes-
sional behaviour, so as to heighten transparency.
Introduction
Clinical practice guidelines (CPGs) synthesize and appraise the available scientific literature to
produce recommendations that assist health care decision-making. [1] They are defined by the
Institute of Medicine (IOM) as “statements that include recommendations intended to opti-
mize patient care that are informed by a systematic review of the evidence and an assessment
of the benefits and harms of alternative care options”. [1] CPG standards and methodologies
have significantly evolved since the 1990s, [2] along with an exponentially expanding number
of CPGs being produced. The Guideline International Network currently counts over 6300
guidelines from 85 countries, [3] almost doubling since 2011, when it documented over 3700
guidelines from 39 countries. [1] Despite such proliferation, many have disputed the accuracy
and integrity of certain CPGs [4] and warned about the limitations, and potential harms from
guidelines that fail to meet quality standards. [5]
Even in an era of evidence-based medicine with highly structured approaches to grading
the quality of the evidence and strength of each recommendation, CPG developers still con-
front incomplete, imperfect or contradictory scientific evidence. Data and evidentiary voids
on CPGs issues sometimes oblige participating experts to make subjective assessments. Rec-
ommendations are therefore influenced by the guideline panelists’ personal input and percep-
tions, especially when the science is unclear. In situations where the quality of CPGs is
compromised, the value of the recommendations produced is undermined. The impact may
reach medical standards, policy and financing, but “[t]he greatest danger of flawed clinical
guidelines is to patients”, potentially resulting in “suboptimal, ineffective, or harmful prac-
tices.” [5] Indeed, “flawed” CPGs can, for instance, provide inaccurate or biased clinical infor-
mation, impose unnecessary interventions, or have limited applicability.
Unsurprisingly, then, to ensure the quality, impartiality and ethical integrity of guidelines,
conflicts of interest (COIs) in CPGs have been the subject of increasing awareness, scrutiny
and standards. [6, 7] The CPG process has been critiqued for pervasive and predominant,
undisclosed, underreported and inaccurate, or poorly managed financial COIs (FCOIs). [8–
12] Accordingly, an important focus over the last decade has been on understanding, identify-
ing and addressing FCOIs as a source of bias in CPGs. In various countries, the management
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of FCOIs has been recommended or mandated. [1, 13] A 2011 report from the IOM addresses
the challenges posed, and notes the role of transparency in the CPG process. Drawing on inter-
disciplinary literature, the IOM urges “provision of information to CPG users that enables
them to understand how recommendations were derived and who developed them”. [1]
Transparency, it is thought, promotes accountability to professional peers by divulging poten-
tially biasing factors. Such transparency, in turn, is thought to advance impartial, independent
CPGs. Doing so is consistent with ethical values of candor, virtue and trustworthiness.
In practice, the disclosure of FCOIs is the enabling process for transparency. Indeed, disclo-
sure has become the implementing transparency norm over the last decade. [1, 6, 14] The liter-
ature indicates that even if a lack of uniform international standards raises important ethics
challenges for transnational CPGs, CPGs grounded on impartiality depend on effective pro-
cess and forms for FCOI declarations, as integral parts of coherent CPG ethics frameworks.
[15] Typically, FCOIs declarations are reported on generic forms with open-ended questions.
[16] They are completed early in the CPG process, and generally consist of standard forms
issued by the guideline developing body, and are thus not tailored to the topic of the CPGs.
The forms typically require CPG participants to list any relevant financial COI, and may
include additional questions detailing the COIs such as the identification of commercial inter-
ests involved, the nature of the financial relationship, and the amounts received. The manage-
ment of COI is contingent on the proper disclosure and documentation of COIs. However,
there is a paucity of data on the structure of COI disclosure forms that optimally captures rele-
vant FCOI disclosures with high accuracy.
In this research brief, we therefore compare the results of a novel supplementary contextual
disclosure form with a standard form alone for an international CPG. [17] A "contextual" dis-
closure form is specifically tailored to the CPG topic, to enable the declaration process by iden-
tifying commercial entities and relationships that may present a FCOI. It is completed later in
the CPG process, to supplement standard original FCOIs declaration forms. We assessed dec-
larations from both forms, to determine whether a supplementary FCOIs declaration docu-
ment yields additional FCOI information.
Methods
As part of the development of an international CPG on the surveillance for colorectal neoplasia
in inflammatory bowel disease, we compared the results of FCOI declarations from two differ-
ent FCOIs disclosure forms completed by CPG participants. [17] Each participant first com-
pleted a standard FCOIs disclosure form issued by the guideline’s organizing scientific body.
Six month later, at the consensus meeting, they completed a supplementary, detailed and con-
textual FCOIs disclosure form specifically tailored to the CPG. An ad hoc ethics committee
was created to oversee COI issues and this study on COI disclosures.
The international CPG was developed by panel 21 international experts from North Amer-
ica, Europe and Asia (physicians, methodologists, a nurse, and a patient representative), as
well as 8 non-voting participants included for content expertise. [17] All participants who
were neither members of the ethics committee nor members of the CPG’s steering committee
were invited to participate in this COI study. The scope of participation was designed to maxi-
mize efficacy of the two different disclosure forms, and to preserve the accuracy of disclosures.
In the absence of uniform international standards, we adopted institutional COI norms of
one of the key scientific societies for the consensus meeting, the Canadian Association of
Gastroenterology (CAG). CAG has prior experience in CPG development. [18, 19] Six months
prior to the CPG consensus meeting, participants completed CAG’s mandatory, standard
FCOI disclosure form. (S1 File) The form features a blank table for participants to disclose
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relevant financial relations, between participants or family members and commercial entities,
over the last 24 months. The form defines FCOIs as “when outside financial interests or con-
nections influence the ability to act with integrity, objectivity and independence with regards
to the assigned task, and encompass actual, apparent or potential COIs." The definition derives
from CAG adoption, with some of modification [20, 21] of first generational definitions of
FCOIs, such as those of the US Accreditation Council for Continuing Medical Education. [22,
23] Such first generation definitions have since evolved with expanded concepts of COI by
public analysts like the IOM. [24] These second generation approaches often broaden COI def-
initions, sometimes with precise elements like primary and secondary interests, monetary
thresholds and varied time periods for disclosure. [13, 25] Those precisions influenced our
next steps.
To provide context and details that might facilitate the disclosure process, the ad hoc ethics
committee developed a supplementary contextual FCOIs disclosure form. (S2 File) The sup-
plementary form specifically addressed issues, financial relations and commercial entities
identified by the ethics committee as pertinent and posing a potential risk of COI to the spe-
cific CPG topic and recommendations. Since part of the CPG addresses chromoendoscopy—a
technique that uses dyes to identify colonic neoplasia during endoscopy—relevant manufac-
turers of dyes, endoscopes, and endoscopy equipment (e.g., spray catheters, injection needles)
were thus specified on the supplementary form. The form also detailed a checklist of prompt-
ers on the nature and extent of the financial relation: e.g., range of monetary amounts, and
roles played. (Table 1)
The supplementary form was completed during the last stages of the guideline develop-
ment, when participants assembled at the CPG consensus meeting for the final discussion and
voting on recommendations. In an ethics process session at the meeting, prior to final voting,
participants were invited to complete this supplementary contextual FCOIs disclosure form.
(S2 File) Participants also then answered a research questionnaire on COI perception and
management, at the ethics session. (S3 File) Institutional research ethics approval was obtained
from McGill University Health Center, and participants provided written informed consent.
Role of funding source
The CPG process received funding from the Maxine and Jack Zarrow Family Foundation and
Warren K Warren Foundation, which otherwise had no involvement in this study. [17]
Table 1. Elements of a contextual financial conflicts of interest disclosure form.
Timing of disclosure
• Declarations of FCOIs repeated at a time close to the final voting or final consensus meeting
List of all relevant companies related to the topic of the clinical practice guideline
• Direct and indirect associations
• When possible, include all pertinent commercial entities that extend to different countries and
professional background to reflect the composition of the participants
Checkbox for details of each disclosed FCOI
• Role
• Amount
• Nature
• Timing (past and future)
FCOI = financial conflict of interest
https://doi.org/10.1371/journal.pone.0182856.t001
Conflict of interest disclosure forms for clinical practice guidelines
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Results
26 out of 27 participants completed the two FCOIs disclosure forms and answered the ques-
tionnaire on their perception of FCOIs in the guidelines process. The latter revealed that all
participants (26/26) believed that FCOIs need to be disclosed. However, many of them (46%,
12/26) deemed that FCOIs disclosure alone is insufficient to allow full participation in the
CPG process, agreeing that additional FCOIs management strategies may be necessary for par-
ticipants with FCOIs.
In the context of such perceptions on operationalizing transparency, we compared partici-
pants’ declarations of FCOIs through the standard disclosure form with those from the contex-
tual disclosure form. We found discrepancies in the declared content, and presence/absence of
FCOIs. While the number of participants disclosing at least one FCOI remained the same
(30.8%, 8/26), the disclosures were not from the same individuals: two additional participants
disclosed a FCOI; two participants with previous declarations withdrew them. When responses
from the two forms were combined, the number of participants to declare at least one FCOI
increased from 30.8% to 38.5% (10/26). Inconsistencies in reporting were noted in 7/10 –
(70%; 95% CI: 41.6–98.4%) of the FCOI declarations. The discrepancies encompass changes in
FCOIs disclosure status and modifications in the content of disclosed commercial relation-
ships and interests (Table 2). For instance, one participant who disclosed COIs in both forms
listed different commercial interests on each form (Table 2, participant ID 4). Another dis-
closed several COIs in the standard form, but indicated “no COI to disclose” in the second
form (Table 2, participant ID 7). A list of modifications is included in the footnotes of Table 2.
Discussion
Our exercise documented important congruities and divergences in the evolving state-of-the
art of identifying and managing FCOIs in the CPG process.
First, for instance, in response to our COI questionnaire, participants unanimously agreed
that authors of CPGs must disclose COIs. If it has taken some two decades [26] for disclosure
to become an established norm, it functions today as a basic, if imperfect standard and tool of
COI ethics for CPGs. Disclosure remains an imperfect tool, in practice, as understanding of its
actual working have evolved to the point that even the literature that acknowledges its role and
beneficial effects also indicates "disclosures is no panacea," and may generate counter-intuitive,
adverse effects. [27] For instance, studies have shown that through a behavioral phenomenon
of "moral licensing," disclosure sometimes frees conflicted professionals to give more biased
advice. [28] Further understanding of such phenomena should help improve and reform dis-
closure in practice.
Second, our participants divided over how best to manage FCOIs in the CPG process
beyond basic disclosure: 55% thought disclosure suffices; 45% thought disclosure insufficient.
The disagreement reflects divergence from, and continuing debate over, an emergent norm
that has come into prominence in FCOI management within the last decade. Proponents of
the norm reject sole reliance on disclosure as a minimalist management strategy that ignores
refined principles of contemporary FCOI ethics, such as the principle of "proportionality."
It holds that CPG participatory standards should be commensurate with COI risks. [15] Pro-
portionality thus relies on a range of FCOI management tools to addresses COIs risks that
range from minimal, to moderate, to high. On this logic, the IOM, the academic literature,
institutions and increasing COI ethics policies now invoke FCOI management tools beyond
disclosure for significantly conflicted experts. [6] Disclosure begins the FCOI management
process. For moderate to high COI risks, it may extend to limiting conflicted experts participa-
tion in, or outright exclusion—with narrow exceptions—from CPG leadership roles, drafting,
Conflict of interest disclosure forms for clinical practice guidelines
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discussing, voting, etc. Our participants’ difference of views on this strategy captures transi-
tional dynamics of this emergent ethics norm.
Such emergent and pluralistic ethics norms—whether minimalist, proportionate or more
robust—build on disclosure. For example, a strict avoidance strategy for FCOIs looks beyond
managing them to avoiding them. Strict avoidance includes in CPGs only experts without
FCOIs. Doing so maximizes impartiality and works well on issues where expertise without
commercial relations is readily identifiable. Yet, the strategy risks silencing or compromising
essential expertise in areas where the experts are few and the FCOIs minimal or manageable.
[15] Accordingly, more permissive strategies grant experts with FCOIs who offer essential
expertise a limited participatory role such as participating in the discussion process, but not in
voting on recommendations [1]. Such management or avoidance of FCOI begins with
Table 2. Summary of financial conflict of interest disclosure using a standard disclosure from and contextual disclosure form.
Participant
ID
Standard FCOI
disclosure form
Contextual FCOI
disclosure form
Change in
disclosure status
Change in
disclosure content
only
Description of change
1 Y Y N N No change
2 Y Y N N No change
3 Y Y N N No change
4 Y Y N Y Change in disclosure content 1
5 Y Y N Y Change in disclosure (new FCOI added) 2
6 Y Y N Y Change in disclosure content3
7 Y N Y - Disclosure in standard form but not in
contextual form 4
8 N Y Y - No disclosure in standard from but disclosure
in contextual form 5
9 Y N Y - Disclosure in standard form but not in
contextual form 6
10 N Y Y - Declared "no" in both forms, but still disclosed
and listed commercial entities in contextual
form 7
Total (Y) 8 8 4 3 Total with changes 7
COI = conflict of interest, FCOI = financial conflicts of interest, ID = identification, N = no, Y = yes.
1 This participant disclosed four COIs with commercial entities in the standard form. In the contextual form, the participant disclosed a COI with only one
commercial entity (different from the prior four disclosed). None of the four COIs initially disclosed (standard form) were part of the listing of relevant
commercial interests, however the one COI disclosed using the contextual form was with a commercial entity included in the listing.
2 This participant disclosed two COI in the standard form. With the contextual form, the participant again disclosed the same two COIs, and added two
additional commercial entities that the ethics committee had identified as relevant commercial entities (for a total of four COIs).
3 This participant disclosed financial relations with 50 commercial entities in the standard disclosure form. Only one of the entities had been identified as a
relevant commercial entities provided in the contextual form. In the contextual form, the participant answered “yes” to having COIs, but did not name or
detail them.
4 This participant disclosed financials relations with seven commercial entities in the standard disclosure form. None of the seven had been identified as
relevant commercial entities listed in the contextual form. In the contextual form, the participant disclosed no COIs.
5 This participant answered “no COI to disclose” in the standard form. However the participant disclosed three COIs with commercial entities listed in the
contextual form.
6 This participant disclosed COIs with 17 commercial entities in the standard disclosure form. Only one of them was included in the listing of relevant
commercial entities provided with the contextual form. In the contextual form, the participant did not disclose any COI.
7 This participant answered “no COI to disclose” in both the standard and contextual form. However, in the contextual form the participant identified a COI
with one commercial entity identified as relevant commercial entities detailed in the contextual form.
https://doi.org/10.1371/journal.pone.0182856.t002
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identifying participants’ FCOIs. Such identification depends in turn on accurate, effective
disclosures.
Thirdly, our study thus documents divergence between the principle of transparency and
the actual practice of declaring financial interests with disclosure forms. Declarations of FCOIs
function at the crossroads of disclosure ethics for CPGs. Declarations depend on honest self-
reporting, framed by FCOIs procedures and disclosure forms. Disclosure forms translate the
ethical principle of transparency into practice; by applying COIs definitions, monetary disclo-
sure thresholds, the scope of financial relations, etc., to the declaration process. Their effective-
ness depends on diverse factors: their interpretation, clarity and relevance, length or brevity,
etc. The forms must strike balances. Given such considerations, a deeper understanding of
their effectiveness is compromised by scant literature on their comparative design, impact and
actual workings. The literature holds few, if any, empirical studies of the effectiveness of alter-
native FCOIs disclosure forms for CPGs.
In our study of disclosure forms and process, we evaluated the yield of administering two
FCOI disclosure forms at two different times. We supplemented the original generic form
with a detailed contextual form administered six months later. The latter afforded participants
a second opportunity to refresh their recollection and to declare financial interests with more
precise information, checklists and questions on relevant commercial relations. The result of
administering both yielded more and revised FCOIs declarations. When we compared FCOIs
declared on the contextual and generic forms, among those who reported a FCOI in either
form, we found discrepancies in 70% of them (Table 2).
Our findings demonstrate important variability in disclosed FCOIs between a standard
generic and a supplementary contextual disclosure form. How so? We discern an interplay of
temporal, content, interpretive, and behavioral factors. If some revisions came from the later
administration of the contextual form, timing alone unlikely accounts for their magnitude.
Facial accountability to peers, [26] and the immediacy and synergy of the CPG meeting may
have also prompted participants towards more probing analysis of their financial relations.
They did so with more enabling disclosure forms that detailed a checklist of relevant commer-
cial entities and products known in the clinical field. Such specificity likely functions as contex-
tual enabler to the declaration process to heighten the utility of the supplementary form.
Indeed, detailed and precise content in FCOIs declaration forms reduces ambiguity and gener-
ality, [29, 30] thus diminishing the risks of forgetting, ignoring, misinterpreting or misreport-
ing relevant, significant financial relations. As such, the effectiveness of a FCOI disclosure
form may be enhanced or compromised by the degree of clarity, context and precision on key
conceptual and operational issues. For instance, if a form requires disclosure of "direct" and
"indirect" or "significant" financial relations with "relevant" commercial entities but does not
meaningfully define or illustrate the concepts, what shall participants declare? Some may judge
as insignificant, and not declarable, $5000.00 in research support from a manufacturer of a
device moderately implicated by a CPG. Other participants may reach the opposite conclusion.
Greater clarity, precision, and contextual guidance likely reduce the risk of erroneous (non)
declarations. We judge participants’ revised declarations as likely more accurate, because they
flow from non-generic, narrower questions and contextual FCOIs information.
Our findings mirror similar results from studies on disclosure forms for authors of medical
articles. Generic FCOIs disclosure forms with opened-ended questions prove sub-optimal due
to their generality and vagueness; forms with narrow, contextual, and detailed prompters
prove more effective partly because precision leaves less room for interpretation. [29, 30] If
such findings suggest a need to revise generic open-ended forms, the insights remain indicia
that merit further rigorous interdisciplinary reflection and research. Some research indicates,
for instance, that whether, when and where one signs and pledges honesty in formal
Conflict of interest disclosure forms for clinical practice guidelines
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declarations influences ethical accountability and accuracy of completed forms. [31] Studies
on "framing effects" further suggest that how a question or issue is framed may generate auto-
mated versus thoughtful ethical responses. [32] Finally from a behavioral science perspective
on "nudge-theory" ethics, the second contextual form arguably functioned as a more potent
moral symbol of ethical conduct, which effectively nudged professionals towards higher ethical
vigilance, accountability [33] and enhanced disclosures once peers were assembled.
Limitations
The small number of participants limits the generalizability of findings. A lack of uniform, har-
monized international FCOI standards likely makes results contextual. The use of more or less
stringent FCOI definitions, thresholds, disclosure and participation criteria may influence
results. Our study design did not control for behavioral, interpretive, temporal or form-con-
tent dimensions of FCOIs declarations. Larger studies in future research may do so, to build
empirical evidence of effective FCOIs disclosure forms and practice.
Conclusions
The declaration of FCOIs remains a critical component of the ethical integrity of CPGs. Full,
accurate disclosures advance transparency ethics. Un-declared, inaccurate or under-declared
FCOIs undermine transparency. Our experience with generic and subsequent contextual
FCOIs declaration forms in an international CPG yielded higher disclosure rates. The results
suggest that precise, contextual content of disclosure forms may effectively interface with tem-
poral, interpretive and behavioral factors to enable more complete, accurate declarations. The
search for optimal FCOIs forms and disclosure process should continue with heightened anal-
yses and research on how such factors best interface to advance transparency ethics.
Supporting information
S1 File. Standard financial conflicts of interest disclosure form.
(PDF)
S2 File. Supplementary contextual financial conflicts of interest disclosure form.
(PDF)
S3 File. Questionnaire on the perception of financial conflicts of interest.
(PDF)
S4 File. Financial conflict of interest disclosure of the SCENIC guideline panel members.
(DOCX)
Acknowledgments
We would like to thank the SCENIC Consensus meeting participants: James E. East, BSc,
MBChB, MD (Res), FRCP (John Radcliffe Hospital, University of Oxford, Oxford, United
Kingdom) Francis A. Farraye, MD, MSc (Boston University, Boston, Massachusetts, United
States) Brian Feagan, MD, MSc (Roberts Research Institute, University of Western Ontario,
Canada) John Ioannidis, MD, DSc (Stanford University, Palo Alto, California, United States)
Ralf Kiesslich, MD, PhD (Johannes Gutenberg University, Mainz, Germany) Michael Krier,
MD (Brooke Army Medical Center/San Antonio Military Medical Center, San Antonio,
Texas, United States) Takayuki Matsumoto, MD (Iwate Medical University, Morioka, Japan)
Robert P. McCabe, MD (Minnesota Gastroenterology, Minneapolis, Minnesota, United States)
Conflict of interest disclosure forms for clinical practice guidelines
PLOS ONE | https://doi.org/10.1371/journal.pone.0182856 August 25, 2017 8 / 11
Klaus Mo¨nkemu¨ller, MD, PhD (University of Alabama, Birmingham, Alabama, United States)
Robert Odze, MD (Brigham & Women’s, Boston, Massachusetts, United States) Michael
Picco, MD, PhD (Mayo Clinic, Jacksonville, Florida, United States) David T. Rubin, MD (Uni-
versity of Chicago Medicine, Chicago, Illinois, United States) Michele Rubin, RN (Society of
Gastroenterology Nurses and Associates, University of Chicago Medicine, Chicago, Illinois,
United States) Carlos A. Rubio, MD, PhD (Karolinska Institute and University Hospital,
Stockholm, Sweden) Matthew D. Rutter, MBBS, MD, FRCP (University Hospital of North
Tees, Teesside, United Kingdom) Andres Sanchez-Yague, MD (Hospital Costa del Sol, Mar-
bella, Spain) Silvia Sanduleanu, MD, PhD (University of Maastricht, Maastricht, Netherlands)
Amandeep Shergill, MD (Veterans Affairs San Francisco; University of California, San Fran-
cisco; San Francisco California, United States) Thomas Ullman, MD (Mount Sinai, New York,
New York, United States) Fernando Velayos, MD (University of California, San Francisco; San
Francisco, California, United States) Douglas Yakich (Crohn’s and Colitis Foundation of
America) Yu-Xiao Yang, MD, MSCE (University of Pennsylvania, Philadelphia, Pennsylvania,
United States).
Author Contributions
Conceptualization: Yidan Lu, Derek J. Jones, Nour Sharara, Tonya Kaltenbach, Alan Barkun.
Data curation: Yidan Lu, Nour Sharara, Alan Barkun.
Formal analysis: Yidan Lu, Nour Sharara, Alan Barkun.
Investigation: Yidan Lu, Derek J. Jones, Nour Sharara, Alan Barkun.
Methodology: Yidan Lu, Derek J. Jones, Alan Barkun.
Project administration: Yidan Lu, Derek J. Jones, Tonya Kaltenbach, Alan Barkun.
Supervision: Alan Barkun.
Writing – original draft: Yidan Lu, Derek J. Jones, Alan Barkun.
Writing – review & editing: Yidan Lu, Derek J. Jones, Nour Sharara, Tonya Kaltenbach,
Loren Laine, Kenneth McQuaid, Roy Soetikno, Venkataraman Subramanian, Alan Barkun.
References
1. Institute of Medicine. Clinical Practice Guidelines We Can Trust. Graham Robin, Mancher Michelle,
Wolman Dianne Miller, Greenfield Sheldon, Steinberg E, editors. Washington, D.C.: The National
Academies Press; 2011.
2. Kredo T, Bernhardsson S, Machingaidze S, Young T, Louw Q, Ochodo E, et al. Guide to clinical practice
guidelines: the current state of play. Int J Qual Health Care. 2016; 28(1):122–8. https://doi.org/10.1093/
intqhc/mzv115 PMID: 26796486
3. Guidelines International Network. International Guideline Library 2017 [updated Nov 18, 2016. http://
www.g-i-n.net/library/international-guidelines-library/international-guidelines-library.
4. Eichacker PQ, Natanson C, Danner RL. Surviving sepsis—practice guidelines, marketing campaigns,
and Eli Lilly. N Engl J Med. 2006; 355(16):1640–2. https://doi.org/10.1056/NEJMp068197 PMID:
17050887
5. Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Clinical guidelines: potential benefits, limita-
tions, and harms of clinical guidelines. Bmj. 1999; 318(7182):527–30. PMID: 10024268
6. Institute of Medicine (US) Committee on Conflict of Interest in Medical Research E, and Practice,. Lo B,
Field MJ, editors. Washington (DC) 2009.
7. Norris SL, Holmer HK, Ogden LA, Burda BU. Conflict of interest in clinical practice guideline develop-
ment: a systematic review. PLoS One. 2011; 6(10):e25153. https://doi.org/10.1371/journal.pone.
0025153 PMID: 22039406
Conflict of interest disclosure forms for clinical practice guidelines
PLOS ONE | https://doi.org/10.1371/journal.pone.0182856 August 25, 2017 9 / 11
8. Cosgrove L, Bursztajn HJ, Erlich DR, Wheeler EE, Shaughnessy AF. Conflicts of interest and the quality
of recommendations in clinical guidelines. J Eval Clin Pract. 2013; 19(4):674–81. https://doi.org/10.
1111/jep.12016 PMID: 23731207
9. Pham-Kanter G. Revisiting financial conflicts of interest in FDA advisory committees. Milbank Q. 2014;
92(3):446–70. https://doi.org/10.1111/1468-0009.12073 PMID: 25199895
10. Bindslev JB, Schroll J, Gotzsche PC, Lundh A. Underreporting of conflicts of interest in clinical practice
guidelines: cross sectional study. BMC Med Ethics. 2013; 14:19. https://doi.org/10.1186/1472-6939-14-
19 PMID: 23642105
11. Lenzer J, Hoffman JR, Furberg CD, Ioannidis JP, Guideline Panel Review Working G. Ensuring the
integrity of clinical practice guidelines: a tool for protecting patients. Bmj. 2013; 347:f5535. https://doi.
org/10.1136/bmj.f5535 PMID: 24046286
12. Classen DC, Mermel LA. Specialty Society Clinical Practice Guidelines: Time for Evolution or Revolu-
tion? JAMA. 2015; 314(9):871–2. https://doi.org/10.1001/jama.2015.7462 PMID: 26237739
13. National Institute for Health and Care Excellence. Policy on Conflicts of Interest. 2014 September 2014.
Report No.: Version 2.5.
14. Schunemann HJ, Al-Ansary LA, Forland F, Kersten S, Komulainen J, Kopp IB, et al. Guidelines Interna-
tional Network: Principles for Disclosure of Interests and Management of Conflicts in Guidelines. Ann
Intern Med. 2015; 163(7):548–53. https://doi.org/10.7326/M14-1885 PMID: 26436619
15. Jones DJ, Barkun AN, Lu Y, Enns R, Sinclair P, Martel M, et al. Conflicts of interest ethics: silencing
expertise in the development of international clinical practice guidelines. Ann Intern Med. 2012; 156
(11):809–16, W-283. https://doi.org/10.7326/0003-4819-156-11-201206050-00008 PMID: 22665816
16. Institute of Medicine (US) Committee on Conflict of Interest in Medical Research E, and Practice,. In: Lo
B, Field MJ, editors. Conflict of Interest in Medical Research, Education, and Practice. The National
Academies Collection: Reports funded by National Institutes of Health. Washington (DC)2009. p. 64–7,
71.
17. Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R, et al. SCENIC international
consensus statement on surveillance and management of dysplasia in inflammatory bowel disease.
Gastroenterology. 2015; 148(3):639–51 e28. https://doi.org/10.1053/j.gastro.2015.01.031 PMID:
25702852
18. Barkun AN, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M, et al. International consensus recom-
mendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern
Med. 2010; 152(2):101–13. https://doi.org/10.7326/0003-4819-152-2-201001190-00009 PMID:
20083829
19. Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, et al. The Toronto Consensus
for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology. 2016.
20. Singh H, Leontiadis GI, Hookey L, Enns R, Bistritz L, Rioux LC, et al. Canadian Association of Gastro-
enterology policy on the application for, and implementation of, clinical practice guidelines. Can J Gas-
troenterol Hepatol. 2014; 28(9):473–80. PMID: 25314352
21. Canadian Association of Gastroenterology. Policy on the application for, and implementation of, clinical
practice guidelines. 2008 [version June 13 2008:[
22. Accreditation Council for Continuing Medical Education. Standards for Commercial Support: Standards
to Ensure Independence in CME Activities Chicago2012 [http://www.accme.org/requirements/
accreditation-requirements-cme-providers/standards-for-commercial-support.
23. Accreditation Council for Continuing Medical Education. Standards for Commercial Support: Standards
to Ensure Independence in CME Activities Chicago2011 [cited 2017.
24. Institute of Medicine (US) Committee on Conflict of Interest in Medical Research E, and Practice,. In: Lo
B, Field MJ, editors. Conflict of Interest in Medical Research, Education, and Practice. Washington
(DC): The National Academies Collection; 2009. p. 189–90.
25. National Institues of Health. Responsibility of Applicants for Promoting Objectivity in Research for
Which Public Health Service Funding Is Sought and Responsible Prospective Contractors. Federal
Register. 2011; 76(165):53256–93. PMID: 21894659
26. Stelfox HT, Chua G, O’Rourke K, Detsky AS. Conflict of interest in the debate over calcium-channel
antagonists. N Engl J Med. 1998; 338(2):101–6. https://doi.org/10.1056/NEJM199801083380206
PMID: 9420342
27. Loewenstein G, Sah S, Cain DM. The Unintended Consequences of Conflict of Interest Disclosure.
Jama-J Am Med Assoc. 2012; 307(7):669–70.
28. Cain D, Loewenstein G, Moore DA. The Dirt on Coming Clean: Perverse Effects of Disclosing Conflicts
of Interest. The Journal of Legal Studies. 2005; 34(1):1–25.
Conflict of interest disclosure forms for clinical practice guidelines
PLOS ONE | https://doi.org/10.1371/journal.pone.0182856 August 25, 2017 10 / 11
29. Drazen JM, Van Der Weyden MB, Sahni P, Rosenberg J, Marusic A, Laine C, et al. Uniform format for
disclosure of competing interests in ICMJE journals. Lancet. 2009; 374(9699):1395–6. https://doi.org/
10.1016/S0140-6736(09)61796-7 PMID: 19836071
30. Baethge C. The effect of a conflict of interest disclosure form using closed questions on the number of
positive conflicts of interest declared—a controlled study. PeerJ. 2013; 1:e128. https://doi.org/10.7717/
peerj.128 PMID: 24024081
31. Shu LL, Mazar N, Gino F, Ariely D, Bazerman MH. Signing at the beginning makes ethics salient and
decreases dishonest self-reports in comparison to signing at the end. Proc Natl Acad Sci U S A. 2012;
109(38):15197–200. https://doi.org/10.1073/pnas.1209746109 PMID: 22927408
32. Kern MC, Chugh D. Bounded ethicality: the perils of loss framing. Psychol Sci. 2009; 20(3):378–84.
https://doi.org/10.1111/j.1467-9280.2009.02296.x PMID: 19222811
33. Zhang T, Fletcher PO, Gino F, Bazerman MH. Reducing bounded ethicality: How to help individuals
notice and avoid unethical behavior. Organ Dyn. 2015; 44(4):310–7.
Conflict of interest disclosure forms for clinical practice guidelines
PLOS ONE | https://doi.org/10.1371/journal.pone.0182856 August 25, 2017 11 / 11
